Aardvark’s lead candidate ARD-101 is being investigated in a Phase III study for hyperphagia in Prader-Willi syndrome.

Proceeds will support testing of drugs designed to suppress hunger in people with the tough-to-treat rare disease and, ...

Aardvark Therapeutics Inc. made its public market debut Thursday, securing $94 million in its initial public offering (IPO).

During a panel discussion at this year’s Fierce JPM Week—which took place alongside the annual J.P. | This week on “The Top ...

Cystic-fibrosis-focused Sionna Therapeutics is joining the Nasdaq this morning with an upsized public offering, while obesity ...

The offerings reflect an increase in IPO activity that could continue, as four other biotechs recently outlined plans to go ...

Aardvark Therapeutics will debut on Nasdaq at $16/share, to raise $94M for hunger-focused metabolic disease treatments. ARD-101 Phase 3 data expected early 2025.

Alumis Inc. will merge with a Southern California drug developer in a deal that extends the combined companies' cash into ...

Webster has led Kestra since 2014 and prior to that spent about 24 years at Physio-Control, a Redmond-based company that made ...

Financial writer advises caution on Jyong Biotech Ltd. IPO due to high debt, legal issues, and FDA challenges. Click for my ...

Aurion Biotech, Inc. plans $100M IPO for corneal disease treatments, limited competition, Phase 1/2 trials underway with ...

Kestra Medical Technologies, a Kirkland, Wash.-based company selling cardiac monitoring and therapeutic devices, filed for an ...